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CD8-mediated virus inhibition can be detected in HIV-1-positive subjects who naturally control virus replication. Characteriz-
ing the inhibitory function of CD8 T cells during acute HIV-1 infection (AHI) can elucidate the nature of the CD8 responses
that can be rapidly elicited and that contribute to virus control. We examined the timing and HIV-1 antigen specificity of antivi-
ral CD8 T cells during AHI. Autologous and heterologous CD8 T cell antiviral functions were assessed longitudinally during
AHI in five donors from the CHAVI 001 cohort using a CD8 T cell-mediated virus inhibition assay (CD8 VIA) and transmitted/
founder (T/F) viruses. Potent CD8 antiviral responses against heterologous T/F viruses appeared during AHI at the first time
point sampled in each of the 5 donors (Fiebig stages 1/2 to 5). Inhibition of an autologous T/F virus was durable to 48 weeks;
however, inhibition of heterologous responses declined concurrent with the resolution of viremia. HIV-1 viruses from 6 months
postinfection were more resistant to CD8-mediated virus inhibition than cognate T/F viruses, demonstrating that the virus
escapes early from CD8 T cell-mediated inhibition of virus replication. CD8 T cell antigen-specific subsets mediated inhibi-
tion of T/F virus replication via soluble components, and these soluble responses were stimulated by peptide pools that include
epitopes that were shown to drive HIV-1 escape during AHI. These data provide insights into the mechanisms of CD8-mediated
virus inhibition and suggest that functional analyses will be important for determining whether similar antigen-specific virus
inhibition can be induced by T cell-directed vaccine strategies.
During acute human immunodeficiency virus type 1 (HIV-1)infection (AHI), virus replicates rapidly and is typically shed
at high levels in mucosal fluids and circulating blood plasma.
HIV-1-specific CD8 T cells are among the earliest immune re-
sponses that arise before peak viremia and contribute to the initial
viral decline (3, 32), resulting in virus escape mutations within the
first 50 days of infection (22). These cytotoxic T lymphocyte
(CTL)-driven escape mutations that appear rapidly in the trans-
mitted/founder (T/F) virus during acute infection demonstrate
that the initial CD8 T cell response applies pressure on early virus
replication. Vaccine strategies that can elicit rapid and durable
HIV-1-specific CD8 T cell responses from which the T/F virus
cannot escape will probably be critical for inhibiting virus replica-
tion in vivo and for controlling viral load (VL) in the absence of
sterilizing immunity. Recent proof-of-concept vaccine studies in
nonhuman primates (24) have demonstrated that vaccine-elicited
CD8 T cell responses can substantially control virus replication
and contribute to protection. Identifying key attributes of CD8 T
cells that associate with virus control and determining whether
CD8 T cells exert antiviral pressure is important for understand-
ing the quality of CD8 T cell responses that vaccine strategies
should target. A detailed understanding of the functional proper-
ties of CD8 T cells that arise during the time of initial viremic
control in acute infection will inform vaccine design by focusing
on strategies that can decrease viremia.
The phenotypic and functional properties of CD8 T cells that
can mediate natural control of virus replication in an exclusive
group of individuals, virus controllers (VCs), have been charac-
terized (18, 46, 47). Additionally, T cell polyfunctionality (1, 2)
and Gag specificity (6, 28, 48) are associated with viremic control
and a slower disease course in HIV-1-positive individuals. Reduc-
tion in viremia by CD8 T lymphocytes without the lysis of in-
fected cells was demonstrated in simian immunodeficiency virus
(SIV) infection of nonhuman primates (NHP) (27, 31, 58), dem-
onstrating that the antiviral activity of CD8 T lymphocytes in-
cludes soluble components. A recent paper has given evidence that
immune pressure is not limited to cytotoxicity of infected cells
(16), as the total CD8 T cell response to acute infection was
shown to possess a high contribution of MIP-1-producing
CD8 T cells. We also previously demonstrated that the percent-
age of MIP-1-positive CD8 T cells correlated positively with
virus inhibition in virus controllers and vaccinees (18).
Here, we have utilized a novel combination of four assays used
in concert to assess CD8 T cell function during acute HIV-1
infection. The ability of primary CD8 T lymphocytes to inhibit
HIV-1 virus replication (full-length HIV-1 T/F infectious molec-
ular clones) via cell-cell contact and also through soluble mecha-
nisms was determined. Antigen-specific cytokine responses of
these same CD8 T cells were determined both through multipa-
rameter intracellular cytokine-staining assays and antigen-spe-
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cific cytokine secretion in cell culture supernatants. We found
that, following HIV-1 transmission, there was rapid and durable
elicitation of autologous HIV-1-specific CD8 T cell-mediated
inhibition of the T/F virus along with rapid elicitation but less
durable breadth for heterologous transmitted viral species. Simi-
lar to HIV-1 controllers, the functional HIV-1 antigen-specific
CD8 T cells studied here can mediate inhibition of virus by sol-
uble components. In one patient with virus escape mutations
from defined CTL function during acute infection (22), we dem-
onstrated functional escape from CD8 T cell-driven virus inhi-
bition. Moreover, this is the first report that CD8 T cells medi-
ating soluble inhibition were of the same antigen specificities as
the CD8 T cells that had previously been determined to drive
virus escape. Altogether, these data demonstrate that multifunc-
tional HIV-1-inhibitory CD8 T cell populations against both
autologous and heterologous circulating HIV-1 strains arise rap-
idly following infection.
MATERIALS AND METHODS
Patient cohorts. HIV-1-positive patients were enrolled through the Cen-
ter for HIV/AIDS Vaccine Immunology HIV-1 infection prospective co-
hort study. CHAVI 001 acute patients were identified as positive for
HIV-1 viral RNA in plasma but having been negative or discordant for
HIV-1 serology at a screening visit. Blood samples were obtained from
patients at multiple time points over several years, and samples taken
during the acute phase of infection were classified according to the criteria
of Fiebig et al. (17). HIV-1 clade C-positive elite controllers were enrolled
through the chronic arm of the CHAVI 001 cohort. HIV-1 clade B elite
virus controllers were enrolled through the Duke University Medical Cen-
ter adult infectious diseases clinic. Elite controllers included in this study
were antiretroviral therapy naïve, had CD4 lymphocyte counts of more
than 600 per ml of blood, and had viral loads that remained below the level
of detection (48 copies/ml blood) or, in the case of one subject, demon-
strated infrequent, isolated viral RNA blips of 2,500 copies/ml blood.
One additional VC did not control virus to an elite (undetectable) level
but maintained a VL of 2,000 RNA copies/ml. HIV-1-negative control
CD8 T cells were obtained as leukopaks, either from the American Red
Cross or from healthy uninfected donors through the Duke IQAC pro-
gram. The CHAVI Acute and Chronic Cohorts study and the Duke virus
controller study were reviewed and approved by the institutional review
boards of Duke University Medical Center. All participants provided writ-
ten informed consent for study participation.
PBMC isolation and cell subset preparation. Peripheral blood
mononuclear cells (PBMC) were isolated using Ficoll-Paque Plus (GE
Healthcare) density gradient centrifugation. PBMC were frozen (90% fe-
tal bovine serum [FBS]–10% dimethyl sulfoxide) and stored at 180°C
until analyzed. On the day of analysis, cells were thawed in a 37°C water
bath, transferred to prewarmed RPMI 1640 (Gibco/Invitrogen) supple-
mented with 10% heat-inactivated FBS, and examined for recovery and
viability. Cells were activated by OKT3 and anti-CD28 antibodies for 3 to
6 days and cultured in RPMI 1640 supplemented with 20% FBS, penicil-
lin-streptomycin, and 20 U/ml recombinant human interleukin-2 (IL-2)
(PeproTech). Activated T cells were separated into CD8 and CD8 sub-
sets using a CD8 T cell isolation kit and CD8 depletion beads, respec-
tively (Miltenyi Biotech).
Transmitted founder viruses/infectious molecular clones. This
study utilized full-length infectious molecular clones (IMC) (40) for ex-
pressing the T/F virus sequences inferred from CHAVI 001 subjects in-
fected, respectively, with clade B (40, 49) and clade C HIV-1 (H. Ding and
C. Ochsenbauer, unpublished data). The T/F sequence derivation for and
construction of the clade C IMC were conducted essentially as previously
described (40). Virus nomenclature is as follows. Clade B T/F viruses are
CH040.c, CH058.c, CH077.t, and CH106.c. Clade C T/F viruses are
CH042.c, CH162.c, and CH185.c. For subjects 700010077 (CH077) and
700010058 (CH058), escape mutations in CTL epitopes have been dem-
onstrated at 6 months postinfection (22). IMC representing the consensus
sequence of full-length genomes of circulating viruses at the 6-month
sampling time point were constructed using methods involving chemical
synthesis of overlapping subgenomic fragments followed by ligation and
cloning, essentially as described previously (34, 49), and are referred to
CH058.mo6 and CH077.mo6, respectively.
Replication-competent virus stocks of the IMC were generated as de-
scribed previously (15, 18, 29, 40). Briefly, proviral DNA was transfected
into 293T cells by using Fugene HD (Roche). Working stocks were am-
plified by passaging virus in human PBMC (American Red Cross).
PBMC-derived virus supernatants were collected every 2 to 3 days and
filtered through a 0.45-m syringe filter, and titers were determined on
TZM-bl cells (obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, from John C. Kappes,
Xiaoyun Wu, and Tranzyme, Inc.) (12, 43, 56).
CD8 VIA. The ability of primary CD8 T cells to inhibit virus repli-
cation in autologous CD4 T cell-enriched targets was measured using an
adaptation of a previously described CD8 virus inhibition assay (CD8
VIA) (18). In brief, PBMC targets were depleted of CD8 T cells by mag-
netic bead separation as described above. CD8 T cell effectors were iso-
lated by negative selection using the CD8 T cell isolation kit (Miltenyi).
Target PBMC were infected by spinoculation at 1,200  g for 2 h at a
multiplicity of infection (MOI) of 0.1. Following spinoculation, infected
targets were plated at 2.25  104 cells per well in a flat-bottom 96-well
tissue culture plate. CD8 effectors were serially diluted 2-fold from 4.5 
105 to 5.6  104 cells/ml and added to autologous infected targets at
corresponding effector-to-target (E/T) ratios of 2:1, 1:1, 1:2, and 1:4. The
infectivity controls consisted of infected targets without added CD8 ef-
fectors. Cultures were incubated at 37°C and 5% CO2 for 6 to 7 days with
a change of 50% fresh medium at day 3. Virus production was measured
at day 6 or 7 by transfer of supernatants onto TZM-bl cells. A single dose
of supernatant was transferred for all wells, and in addition, supernatants
from control wells and 2:1 E/T wells were titrated on TZM-bl cells by serial
dilution. Following 2 days of incubation, the TZM-bl cells were lysed and
firefly luciferase measured using the BriteLite Plus reagent (Perkin Elmer)
on a Berthold EG&G luminometer. Virus inhibition was calculated as
either the log reduction in relative light units (RLU) from wells containing
CD8 T cells compared with that in control wells lacking CD8 T cells or
the log reduction in virus titer (50% tissue culture infective dose
[TCID50]) at a 2:1 E/T ratio compared with the reduction in the infectivity
control virus titer.
HIV-1 peptide stimulation and soluble-factor virus inhibition assay
(HIV-1-specific CD8 transwell VIA). Twelve pools of overlapping 15-
amino-acid peptides that represent potential T cell epitopes (PTE) (33,
37) (obtained through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH) were created to represent the fol-
lowing HIV-1 regions based on HXB2 position: Env1 4 to 296, Env2 297 to
488, Env3 489 to 602, Env4 603 to 840, Gag1 1 to 128, Gag2 131 to 361,
Gag3 362 to 486, Pol1 1 to 152, Pol2 156 to 447, Pol3 452 to 709, Pol4 711
to 988, and Nef 1 to 193. Positively selected CD8 T cells (following 2 days
of rest after separation) were stimulated with peptide pools at 2 g/ml
with anti-CD28 and anti-CD49d (1 g/ml each; Becton Dickinson) in
PBMC medium (as described above) for 5.5 h. Following stimulation,
CD8 cells were diluted in PBMC medium to 3.2  105 cells/ml and
aliquots placed in the upper chambers of a 96-well transwell plate (0.4-m
polycarbonate membrane; Corning, Millipore) at 3.2  104 cells per well
(2:1 E/T). Trypsinized TZM-bl cells were added to the bottom chambers
of the transwell plate with DEAE-dextran (15 g/ml) and virus at an MOI
of 0.2. Following 48 h of incubation at 37°C and 5% CO2, virus replication
was measured by quantification of cell-derived luciferase using BrightLite
reagent (Perkin Elmer) as described above. Virus suppression was deter-
mined as the log reduction in RLU in wells containing CD8 T cells
compared with that in control wells lacking CD8 T cells, and significant
virus inhibition was calculated as 0.2-log reduction in RLU. Virus sup-
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pression from stimulated CD8 cells from an HIV-1-seronegative donor
was subtracted as background for each peptide pool.
Cytokine measurement. Supernatants were collected from the bot-
tom chambers of the transwells (HIV-1-specific CD8 transwell VIA, de-
scribed above) following the 2-day incubation and prior to TZM-bl cell
lysis and were stored at 80°C. Cytokine levels (e.g., macrophage inflam-
matory protein 1 [MIP-1], MIP-1, gamma interferon [IFN-	], inter-
feron-inducible protein of 10 kDa [IP-10], Il-4, and IL-1) were mea-
sured using a Milliplex Map cytokine/chemokine immunoassay Luminex
kit (Millipore) according to the manufacturer’s instructions and as previ-
ously described (51).
Multiparameter intracellular cytokine-staining assay. PBMC were
stimulated with the PTE peptide pools described above. Stimulation with
1 g/ml anti-CD3 (OKT3) and 1 g/ml anti-CD28 was used as positive
controls, as was stimulation with a peptide pool representing the cyto-
megalovirus (CMV) pp65 protein (JPT, Germany). The titer of each an-
tibody was determined to obtain the saturating concentration used for the
final staining. The stimulations were conducted in the presence of 1 g/ml
anti-CD49d monoclonal antibody (MAb) (clone L25; BD), anti-CD107a
phycoerythrin (PE)-Cy5 (clone H4A3; eBioscience), 5 g/ml brefeldin A
(Sigma-Aldrich), and 1 g/ml Golgi Stop (BD) for 5.5 h at 37°C in 5%
CO2. After washing, the cells were stained with aqua blue viability indica-
tor (LIVE/DEAD fixable dead cell stain kit; Invitrogen) in phosphate-
buffered saline for 20 min at room temperature. Cells were then washed
and stained for 20 min at room temperature with a surface stain cocktail
containing anti-CD4-Cy5.5-PE (clone M-T477; Biolegend), anti-CD8-
QD605 (clone RPA-T8; Invitrogen), anti-CD27-Cy7-PE (clone M-T271;
BD Bioscience), anti-CD57-QD565 (clone NK-1; AbD, Serotec; conju-
gated in G. Ferrari’s laboratory), and anti-CD45RO-PE-Texas red (clone
UCHL1; Beckman Coulter). PBMC were subsequently fixed and perme-
abilized with Cytofix/Cytoperm and Perm/Wash buffer (Pharmingen,
San Diego, CA) for 20 min, washed twice, and stained with anti-CD3–
Cy7–antigen-presenting cell (APC) (clone SK7; BD Bioscience), anti-
IFN-	–Alexa Fluor 700 (B27; BD Bioscience), anti-IL-2–APC (clone
MQ1-17H12), anti-MIP-1b–fluorescein isothiocyanate (FITC) (clone
24006; R&D Systems), and perforin PE (clone B-D48; Cell Sciences) for 1
h at 4°C. After washing and fixation, all samples were acquired on a cus-
tom-made LSRII (BD Bioscience, San Jose, CA) within the next 24 h.
Gates were set to include singlet events, live CD3 cells, lymphocytes, and
CD4 and CD8 subsets. From the total CD4 and CD8 populations,
the naïve subset was identified as CD45RO CD27. This subset was
excluded from the subsequent analysis, and only the memory population
was included. Within the memory population, the central memory (CM)
CD45RO CD27 (RO 27), effector (E) CD45RO CD57 (RO
57), and terminal effector (TE) CD45RO CD57 (RO 57) popula-
tions were identified. Antigen-specific populations were identified within
the memory population as single-function cells shown in the sequential
single-cytokine/-chemokine/-degranulation gates. Responses were con-
sidered positive if the percentage of antigen-specific cells was 3-fold above
the background and greater than 0.05% after background subtraction.
Data analysis was performed using FlowJo 8.8.4 software (TreeStar).
Statistical analyses. Statistical analyses were performed using Prism 5
software (GraphPad). Correlations between cytokine expression level and
virus inhibition were calculated using Pearson’s correlations.
RESULTS
Breadth of inhibition of transmitted/founder viruses by acute
CD8 T cells. We examined the breadth of CD8 T cell virus
inhibition during acute infection using primary CD8 T lympho-
cytes from CHAVI 001 acute-infection subjects (Table 1). CD8 T
cells isolated from the peripheral blood during the acute phase of
infection (Fiebig stages 1 through 5) were tested for the ability to
inhibit both autologous and heterologous T/F virus replication in
primary CD4 T lymphocytes. To test the breadth of CD8 T
cell-mediated virus inhibition across relevant circulating clade B
and clade C viruses, a panel of seven full-length T/F IMC and two
6-month full-length IMC were examined in a VIA assay. CD8 T
cells isolated during acute infection inhibited both autologous and
heterologous viruses at the earliest time points examined with a
trend toward a higher magnitude of inhibition of autologous vi-
ruses. Acute CD8 T cells reduced T/F virus titers by a mean of 1.5
logs more than seronegative controls at an E/T ratio of 2:1 (Fig. 1).
We previously demonstrated that virus controllers have potent
CD8 antiviral responses against IMC that contain T/F envelope
sequences (18). Here, we refined our studies by utilizing recently
constructed IMC of both clade B (40) and C HIV-1 that represent
the complete HIV-1 T/F genomes inferred from subjects during
acute infection. Additionally, we tested CD8 T cells from four
elite controllers from the CHAVI 001 established-infection cohort
(presumed clade C infection, based on clade C accounting for
100% of HIV-1 sequences analyzed from these clinical sites) and
one elite controller from the Duke infectious diseases clinic to
compare to the breadth of acute CD8 T cell responses. Similar to
CD8 T cells from acute infection, elite controllers exhibited a
breadth of inhibition of the panel of T/F viruses with a magnitude
that was 1.8 logs greater than that of seronegative controls. While
the mean potency exerted by acute CD8 T cells against T/F vi-
TABLE 1 Demographics and clinical data
Patient Age Ethnicity Gender Cohorta Clade
HLA
CD4 range VL range ARTA B C
700010077 (CH077) 23 AA M Acute B 02/02 53/57 04/18 664–914 1.8e5–1.7e3 Naïve
700010106 (CH106) 56 W M Acute B 11/24 35/35 04/04 277–869 1.5e7–50 Week 1
701010199 (CH199) 19 AA M Acute B 66/30 58/42 03/17 485–546 1.2e5–3.5e3 Naïve
702010157 (CH157) 21 African M Acute Cb 24/34 44/– 04/04 256–382 7.5e5–7.6e3 Naïve
702010736 (CH736) 20 African M Acute Cb 29/29 42/45 04/06 213–367 7.5e5–1.6e5 Naïve
707010616 (CH616) 62 African F EC Cb 02/68 07/57 07/07 889–2397 40 Naïvec
707010668 (CH668) 42 African F EC Cb 01/30 42/81 17/18 610–743 48 Naïvec
707010735 (CH735) 38 African F EC Cb 29/30 14/42 08/05 439–715 40 Naïvec
707010774 (CH774) 24 African F EC Cb 30/68 53/57 04/18 1134–1151 57 Naïvec
VC18 0873–5017 48 W M EC B 02/03 27/35 01/04 1222 209 Naïvec
VC9 0873–5014 58 W M VC B 03 07/40 03/07 848 1,020 Naïve
a EC, elite controllers; VC, virus controllers.
b Presumed virus clade based on geographic location.
c ART status based on clinical data.
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ruses was lower than that exerted by elite controllers, this differ-
ence was not found to be significant.
Ontogeny and durability of inhibition of heterologous and
autologous T/F viruses by acute CD8 T cells. To examine the
ontogeny of CD8 T cell virus inhibition, we examined CD8 T
cells isolated longitudinally over the course of the earliest stages of
acute infection from four HIV-1-infected donors. We first mea-
sured the ontogeny and durability of the acute CD8 T cell-me-
diated response with a panel of heterologous T/F viruses using the
CD8 VIA (Fig. 2). CD8 T cells from both presumed clade B
infections (subjects CH199 and CH106) and presumed clade C
infections (subjects CH157 and CH736) and isolated from Fiebig
stages 1 to 5 of acute infection broadly mediated the inhibition of
several heterologous viruses. Inhibition of virus from both
matched and mismatched clades was observed, with 91% of het-
erologous viruses inhibited by 1 log at the earliest time point
tested (Fig. 2 and Table 2). As shown in Fig. 2, the potency of mean
virus inhibition of heterologous T/F viruses mirrors the dynamics
of virus load over time, suggesting that the level of inhibitory
activity might be dependent on constant antigen stimulation. We
then measured the ontogeny and durability of autologous CD8 T
cell-mediated virus inhibition using longitudinal acute samples
and T/F virus from the same subject, CH106 (Fig. 3). While CD8
inhibition of heterologous virus in this subject rapidly declined 1
to 2 logs concurrent with the resolution of viremia (after antiret-
roviral therapy [ART]) (Table 1 and Fig. 2 and 3), CD8-mediated
inhibition of autologous T/F virus was maintained at peak levels
48 weeks following enrollment (Fig. 3). These data demonstrate
the rapid and durable development of the virus-specific inhibitory
CD8 T cell memory response despite reduced viremia, and yet
they also highlight the limitation of the CD8 T cell response to
novel (heterologous) viruses in the requirement for continuous
antigen stimulation.
Impaired CD8 T cell inhibition of early T cell escape viruses
compared to inhibition of T/F viruses. To determine whether
CD8-mediated virus inhibition could have a role in driving virus
escape, we examined cells obtained at three consecutive early time
points from an acute HIV-1-positive donor beginning at Fiebig
stage 4 (subject CH077). Epitopic changes in the virus consistent
with virus escape from CD8 T cell IFN-	 responses in this HLA-
B57 donor were characterized in previous studies (16, 22). Using
the CD8 VIA, we examined the ability of CD8 cells isolated dur-
ing acute infection to inhibit replication of the autologous T/F
virus and a later autologous IMC which represents the consensus
sequence of circulating viruses at 6 months following enrollment
and contains identified T cell escape mutations. In addition, we
examined virus inhibition of paired heterologous T/F and
6-month viruses derived from another HLA-B57 donor (subject
CH058). We found that both autologous and heterologous T/F
viruses were inhibited by 2 logs during a span of 3 weeks during
acute infection (Fig. 4A). However, CD8 T cells obtained during
acute infection were impaired in their ability to inhibit the
6-month autologous and heterologous viruses. These 6-month
viruses were not significantly resistant to inhibition by heterolo-
gous (not HLA-matched) acute-infection CD8 T cells (Fig. 4B),
suggesting a common mechanism of escape, possibly to HLA-
B57-restricted epitopes, exerted by autologous donor CD8 T
cells. These data are congruent with previous findings that virus
rapidly escapes from CD8 T cell responses in this donor. Taken
together, these data demonstrate that virus can rapidly escape
from specific CD8 T cell responses during acute infection, di-
minishing the ability of CD8 T cells to control virus replication
in early infection.
Acute-infection CD8 T cells can inhibit transmitted/
founder viruses via soluble-factor virus inhibition. We previ-
ously demonstrated that virus inhibition correlates with MIP-1
expression (18) and that strongly suppressive CD8 T cells up-
regulate the expression of inflammatory cytokines and chemo-
kines, including MIP-1, MIP-1, IFN-	, IP-10, and IL-1 (51).
To evaluate whether antigen-specific acute-infection CD8 T cells
with inhibitory capacity against T/F viruses can also mediate sol-
uble-factor virus inhibition, we employed a novel assay using a
transwell system to measure the inhibition of T/F virus infection
of target cells in one chamber following HIV-1 peptide stimula-
tion of CD8 T cells present in the other chamber. First, CD8 T
cells from a virus controller (VC9) were examined for the ability to
mediate soluble HIV-1 inhibition following HIV-1 antigen stim-
ulation. Aliquots of CD8 T cells were stimulated with pools of
HIV-1 peptides representing potential T cell epitopes (PTE) and
cultured with HIV-1-infected TZM-bl cells separated from the
effector cells by a semipermeable membrane. As shown in Fig. 5A,
soluble inhibitory activity was stimulated by multiple HIV-1 pep-
tide pools, with the most potent responses resulting from Gag2,
Pol2, and Nef peptide pool stimulation. Both R5-tropic T/F vi-
ruses and an X4-tropic laboratory-adapted virus (IIIB) were in-
hibited via soluble CD8 T cell responses. Virus inhibition corre-
lated with the percentage of HIV-1-specific CD8 cells expressing
CD107a, MIP-1, and IFN-	, as determined by flow cytometric
FIG 1 CD8 T cells from HIV-1 donors before or during the time of serocon-
version suppress T/F viruses at levels similar to suppression in elite controllers.
CD8 T cells isolated from 3 seronegative donors, 5 HIV-1-positive donors
(Fiebig score of 5), and 5 HIV-1-positive elite controllers were tested for
antiviral activity against a panel of 7 T/F IMC in the CD8 VIA. Dots represent
the log reduction in virus replication (RLU) for each CD8 donor against a
single virus at an E/T ratio of 2:1 compared to the results from a CD8-depleted
infection control. Statistical significance was determined by using the mean
virus inhibition across T/F viruses for each donor (Student’s t test). The dotted
line indicates a log inhibition cutoff for positivity of 0.96 (3 standard deviations
above the mean seronegative donor T/F virus inhibition).
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analysis (Fig. 5B). Following the 2-day inhibition assay, cytokine
levels in supernatants drawn from the bottom chamber of the
transwell system were measured. Antigen-specific virus inhibition
significantly correlated with secretion of cytokines/chemokines
(MIP-1, MIP-1, IFN-	 IP-10, and IL-1), as shown in Fig. 5C.
Next, we determined whether CD8 T cells from acute HIV-1
infection could mediate antigen-specific soluble-factor inhibition
similar to that observed in a virus controller. CD8 T cells isolated
longitudinally from five subjects with acute HIV-1, CH106,
CH199, CH157, CH736 (Fig. 6), and CH077 (Fig. 7), were exam-
ined for the ability to inhibit a clade-matched T/F virus (CH040.c,
clade B, or CH042.c, clade C, respectively). HIV-1 antigen-specific
CD8 T cells from the earliest acute-infection time point exam-
ined were capable of mediating soluble inhibition of T/F virus
replication. In each of the four subjects followed longitudinally
(Fig. 6), who were studied for 8 weeks, the earliest dominant
responses diminished over time, and less potent responses against
a wider range of epitopes began to emerge. The antigen-specific
CD8 T cell responses varied among the acute-infection subjects.
However, in all five subjects, Nef-specific CD8-mediated virus
inhibition was observed, with Gag 2 CD8 T cell responses being
the next most frequent in two of five responders (Fig. 6E). These
data demonstrate, for the first time, that antigen-specific CD8 T
cells from acute HIV-1 infection can mediate soluble-component
inhibition of T/F viruses.
The subsets of antigen-specific CD8 T cells that mediate
inhibition by soluble factors are the same as those that drive
virus escape. Since we demonstrated that virus inhibition by
CD8 T cells from subject CH077 (Fig. 4A) was impaired against
autologous virus carrying T cell escape mutations (CH077.mo6)
but not the T/F virus (CH077.t), we sought to evaluate whether
CD8 T cells from acute infection could mediate antigen-specific
soluble-factor virus inhibition corresponding to the same anti-
gen-specific CD8 T cells that have been shown to drive virus
escape in this subject. Thus, we evaluated the ability of CD8 T
cells from CH077 to inhibit autologous T/F through soluble
FIG 2 CD8 T cell-mediated virus inhibition of heterologous T/F viruses is dynamic during the acute phase of infection. Antiviral activity was measured from
CD8 T cells isolated longitudinally from 4 HIV-1-positive patients (3 ART-naïve and CH106 who began ART at study week 1) during acute infection (shown
as log reduction in virus titer [TCID50] from the results for a CD8-depleted control). Mean inhibition across T/F viruses is shown for 4 patients: (A) 700010199;
(B) 702010157; (C) 702010736; (D) 700010106.
TABLE 2 CD8 T cell-mediated virus inhibition
Wk
Inhibition of viruses examined in patient:





















0 2 1.8–1.8 3 0.9–2.8
1 2 1.1–1.8 5 0.5–2.3 5 0.5–2.3
2 2 1.6–2.1 4 0.9–3.2
3 5 0.9–1.8 2 2.1–2.5 5 0.5–0.9 4 0–2.7
4 5 0–1.4 2 0.4–0.4 5 1.5–2.7 4 0.9–1.8





Ag-Specific CD8 T Cells Inhibit HIV-1 in Acute Infection
June 2012 Volume 86 Number 12 jvi.asm.org 6839
means and in an antigen-specific manner. Using the HIV-1-spe-
cific CD8-transwell VIA assay described above, we found that
acute CD8 T cells from CH077 produced soluble factors capable
of inhibiting autologous T/F viruses, specifically after recognizing
epitopes found within the Env2, Gag2, and Nef regions (Fig. 7A).
These antigen-specific CD8 T cell data add to the previous work
that demonstrated rapid virus escape mutations in these regions
during this same time frame (16, 22). Elevated levels of the cyto-
kines MIP-1, MIP-1, IFN-	, IP-10, and IL-1 were measured
in cell culture supernatants following Env2, Gag2, and Nef peptide
pool stimulation. The concentrations of these cytokines corre-
lated positively with the levels of virus suppression (Fig. 7B and
Table 3). These data further suggest that inhibitory CD8 T cell
populations arise rapidly following infection and are multifunc-
FIG 3 CD8 T cell-mediated inhibition of autologous virus is maintained even in the absence of high viral loads. Antiviral activities exerted by CD8 T cells that
were isolated longitudinally from a clade B-infected HIV-1-positive patient during acute infection are shown as log reductions in titer (TCID50) compared to the
results for the CD8 T cell-depleted control sample. CD8 T cell-mediated inhibition of 3 heterologous T/F viruses (CH040.c, CH058.c, and CH077.t), one
autologous T/F virus (CH106.c), and NL4-3 is shown over 48 weeks for patient 7000010106.
FIG 4 Virus rapidly escapes from CD8-driven pressure exerted early after infection. (A) CD8 T cells isolated from 3 early time points (enrollment to week 3)
were tested in the CD8 VIA for inhibitory capacity against autologous (CH077.t) and heterologous (CH058.c) T/F and 6-month viruses. Inhibition of virus
replication (TCID50) relative to the results for a CD8-depleted control is shown. (B) Inhibition of T/F and paired 6-month virus by CD8
 T cells from
heterologous acute patients is shown as log reduction in virus titer (TCID50) relative to the results for a CD8-depleted control. The range of inhibition for
heterologous donors is shown as log reduction in virus titer at 2:1 E/T.
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tional and that soluble inhibition of HIV-1 replication mediated
by CD8 T cells during acute infection may play a role in driving
virus escape.
DISCUSSION
Identification of the functional properties of CD8 T cells respon-
sible for effective virus control in HIV-1-infected humans will
have a profound impact on vaccine design. In working toward this
goal, it is important to delineate the functional antiviral capacity
and the antigen specificity of HIV-1-specific CD8 T cells that are
elicited during acute infection and are responsible for decreasing
the initial high level of viremia. CD8 T cells are quite heteroge-
neous and are characterized by their capacity to mediate lysis of
HIV-1-specific target cells, secrete cytokine, and proliferate (52).
Virus controllers have potent suppression of viremia due to the
contribution of specific CD8 T cell effector functions (11, 25,
39), and these attributes of effector CD8 T cells are being studied
intensively. Cell surface expression of CD107a is associated with
the capacity of antigen-specific CD8 T cells to eliminate infected
cells and to inhibit HIV-1 replication. Phenotypic markers denot-
ing transitional memory cells are also associated with the ability to
inhibit HIV-1 replication (18, 30). Furthermore, the characteriza-
tion of the cytokine profile of CD8 T cells has identified MIP-1
as a correlate of virus control (16) and virus inhibition (18). In
total, CD8 T cells can inhibit virus replication through either
lysis of infected CD4 T cells or inhibition of virus replication (7,
13, 41, 54, 55, 59). This inhibition may involve suppression
through the release of soluble -chemokines that can directly
block the entry of CCR5-using viruses (8, 14). In this study, we
examined the early ontogeny, magnitude, and virus specificity of
CD8 T cell-mediated virus inhibition. This comprehensive in-
vestigation of acute CD8 T cell-mediated anti-HIV-1 responses,
utilizing complementary assays (Fig. 8), includes characterization
of soluble-factor virus inhibition against autologous and heterol-
ogous full-length T/F infectious molecular clones from clades B
and C during the well-defined early stages of AHI according to
Fiebig et al. (17).
An important indicator of the quality of vaccine-elicited CD8
T cell responses will be the ability of CD8 T cells to inhibit cir-
culating strains of HIV-1. CD8 T cells from acute infection of all
five patients that we examined were able to inhibit multiple T/F
viruses representing current circulating strains. However, this
ability declined over the course of AHI. In CH106, we found that
FIG 5 Soluble inhibition of HIV-1 correlates with cytokine expression in CD8 T cells from a virus controller. Transwell CD8 VIA was used to assess the
soluble-factor inhibitory capacity of PTE peptide-stimulated CD8 T cells from a virus controller. Suppression of virus replication is shown as log reduction in
RLU from the results for an infected TZM-bl control. Background is determined using peptide pool-stimulated CD8 T cells from a seronegative donor and has
been subtracted. (A) Suppression of CH040.c T/F and IIIB viruses by peptide pool-stimulated VC9 CD8 T cells is shown. (B) Each panel shows the percentage
of total CD8 T cells expressing the indicated cytokine of CD107a as determined by flow cytometric analysis. (C) Each panel shows supernatant cytokine levels
as measured by Luminex following peptide stimulation of CD8 T cells and coculture with infected CD4 T cell targets. Lines indicate best fit, by least squares
method. Pearson’s correlations and P values are shown (Prism software).
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inhibition of autologous virus was more durable than heterolo-
gous virus inhibition. This was in contrast to virus controllers,
who demonstrated breadth of virus inhibition well into the
chronic stage of infection. There are many potential explanations
for this difference that warrant further investigation. CD8 T cell
responses that have maintained specificity for autologous epitopes
may have been selectively expanded during acute infection. How-
ever, CD8 T cell responses to more conserved regions across the
virus isolates measured here might not be as readily amplified and
so may represent a decreasing fraction of the total CD8 T cell
response over time. Future studies, where the primary CD8 T
cells from acute infection are not limiting, could test a range of
CD8 effector cells to evaluate the quantitative differences in het-
erologous and autologous CD8 T cell responses. CD8 T cell
inhibition against heterologous T/F viruses may also be more de-
pendent on the level of virus replication (Fig. 2). Further studies
with larger cohorts are needed to determine if the levels of antigen
stimulation and heterologous activity are linked. Alternatively, in
CH106, the preference for the durability of autologous virus inhi-
bition could be due to early ART that results in better preservation
of the immune response, thus maintaining the initial antiviral
response against the T/F virus. Cao et al. (4) studied two acutely
infected subjects using IFN-	 enzyme-linked immunosorbent
spot (ELISPOT) and 51Cr release assays and concluded that the
quality of the earliest CD8 T cell response in HIV-1 infection
may be the best target for HIV-1 vaccine strategies, because these
earliest responses probably develop in the presence of CD4 T cell
help and are able to significantly decrease initial viremia. Simi-
larly, we find that the early CD8 T cell response may provide
insight into the quality of the CD8 T cell responses required for
an effective HIV-1 vaccine.
HIV-1-specific CD8 T cells from acute infection consistently
mediated soluble inhibition of T/F viruses. Although there were
differences among the patients in terms of which HIV-1 peptides
elicited soluble-factor virus inhibition, the ability of Nef-stimu-
lated T cells to mediate soluble inhibition was common to all acute
subjects studied here (Fig. 6). In contrast to virus controllers, we
found that the memory T cell response mediating soluble-factor
FIG 6 CD8 T cells inhibit replication of T/F viruses through antigen-specific release of soluble inhibitors. Transwell CD8 VIA assay was used for longitudinal
assessment of the soluble-factor inhibitory capacity of HIV-1 peptide-stimulated CD8 T cells from 4 acute donors. Suppression of virus replication is shown as
log reduction in RLU from the results for an infected TZM-bl control. Results for the JR-HVS CD8 T cell line positive control are shown in red. Background is
determined using peptide pool-stimulated CD8 T cells from a seronegative donor and has been subtracted. (A) Soluble-factor suppression of CH040.c virus by
700010106 CD8 T cells. (B) Soluble-factor suppression of CH040.c virus by 701010199 CD8 T cells. (C) Soluble-factor suppression of CH042.c virus by
702010157 CD8 T cells. (D) Soluble-factor suppression of CH042.c virus by 702010736 CD8 T cells. (E) A summary of positive responses seen at enrollment
or week 1 (cutoff of 2.5 standard deviations above the seronegative mean after background subtraction).
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virus inhibition was limited to selected specificities of HIV-1 an-
tigen-stimulated CD8 T cells. Our evaluation of the CD8 anti-
gen-specific soluble HIV-1 inhibitory response is complementary
to the findings of Radebe et al., who recently demonstrated re-
stricted antigen specificity of CD8 T cells and a common Nef
response, as measured by IFN-	 secretion, in a clade C cohort
(45).
In this study, we found that acute CD8 T cell-mediated virus
inhibition was composed of soluble virus-inhibitory factors se-
creted from epitope-specific (Env, Gag, and Nef) CD8 T cells.
FIG 7 Soluble-factor inhibition of autologous T/F virus corresponds with rapid virus escape and correlates with cytokine release. Transwell CD8 VIA was used
for longitudinal assessment of the soluble-factor inhibitory capacity of PTE peptide-stimulated CD8 T cells from an acute patient. Suppression of virus
replication is shown as log reduction in RLU from the results for an infected TZM-bl control. Results for the JR-HVS CD8 T cell line control are shown in red.
Background is determined using peptide pool-stimulated CD8 T cells from a seronegative donor and was subtracted. (A) Suppression of CH077.t T/F virus by
peptide pool-stimulated 700010077 acute CD8 T cells is shown. (B) Each panel shows supernatant cytokine levels as measured by Luminex following peptide
stimulation of CD8 T cells and coculture with infected CD4 T cell targets. Pearson’s correlations and P values are shown (Prism software).
TABLE 3 Correlation of soluble factors and CD8 T cell virus inhibition during acute HIV-1 infection and for an HIV-1-positive virus controllera
Patient, time of
sampling Statistic IFN-	 IL-1 IL-4 IP-10 MIP-1 MIP-1
700010077, enrollment r2 0.886 0.790 0.186 0.871 0.510 0.570
P value 0.0001 0.001 0.185 0.0001 0.003 0.001
701010199, week 1 r2 0.520 0.382 0.348 0.469 0.513 0.669
P value 0.002 0.139 0.026 0.005 0.003 0.0002
702010157, enrollment r2 0.585 0.544 0.0004 0.926 0.402 0.479
P value 0.0001 0.155 0.910 0.0001 0.0001 0.0001
702010736, week 1 r2 0.658 0.768 0.053 0.739 0.950 0.887
P value 0.0008 0.0001 0.471 0.028 0.0001 0.0001
VC9 0873–5014 r2 0.920 0.868 0.135 0.913 0.902 0.868
P value 0.0001 0.0001 0.266 0.0001 0.0001 0.0001
a Supernatant cytokine levels as measured by Luminex following peptide stimulation of CD8 T cells and coculture with infected CD4 T cell targets. Pearson’s correlation
coefficients and P values are shown (Prism).
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-Chemokines are important soluble mediators of control in
HIV-1 infection (13) and have been shown to mediate CD8 T
cell antiviral activity (8). Importantly, CD8 T lymphocytes se-
crete high levels of MIP-1 and MIP-1 that correlate with
asymptomatic HIV-1 infection (9). We have reported that
MIP-1 and CD107a were markers strongly associated with virus
inhibition by virus controllers and HIV-1 vaccinees (18). Further-
more, recent work indicates that MIP-1-expressing CD8 T
lymphocytes exert immune pressure early in HIV-1 infection (16).
Analysis of the cytokine profile released by CD8 T lymphocytes
may aid in determining the CD8 T cell functions that should be
elicited by therapeutics or a protective HIV-1 vaccine. We previ-
ously analyzed the mRNA levels and cytokine secretion from
HIV-1 virus controllers (50) to identify the cytokine profile of
CD8 T lymphocytes that exhibit soluble-factor virus inhibition
(51). Our profile includes several genes studied previously in the
context of CD8 T lymphocyte-mediated virus inhibition (MIP-
1, MIP-1, IL-13, I-309, IP-10, and granulocyte-macrophage
colony-stimulating factor [GM-CSF] [8, 20, 21, 26, 36, 57]). These
results underscore the multifactorial nature of the CD8 T cell
effector response and highlight the need for a better understand-
ing of how these responses are elicited and maintained.
The ability of T/F viruses to escape from CD8 T cell-mediated
virus inhibition had not been previously reported. Notably, we
examined patient CH077, who has documented virus escape from
CTL, and measured both total and soluble-factor virus inhibition
of the autologous T/F virus from this subject. We found that that
HIV-1 CD8 T cells that mediated inhibition of autologous T/F
virus (Fig. 4) were of the same antigen specificity as had been
previously shown to be responsible for virus escape (22). Specifi-
cally, the Gag2 responses include cells responsive to the IW9 and
TW10 epitopes present in this individual, from which escape was
documented between 102 and 159 days following screening. Fur-
thermore, rapid virus escape from regions represented in the Env4
and Nef pools was documented. Together, these data suggest that
MHC peptide-induced stimulation produces factors that decrease
virus replication. These factors may be commonly stimulated in
memory cells, are broadly active, and are mediated from the same
antigen-specific CD8 T cell subsets that are capable of driving
virus escape. Further analysis of HIV-1 peptide stimulation in a
virus controller demonstrated significant increases in specific sol-
uble antiviral activity, and this activity correlated positively with
the levels of cells expressing CD107a, IFN-	, and MIP-1 (P 
0.001, Pearson’s correlation) but not IL-2. We previously identi-
fied that this CD8 T cell phenotype in virus controllers and vac-
cinees correlated with the capacity to inhibit virus replication (18).
This study was uniquely suited to address the question of whether
virus escape from known epitope-specific CD8 T cell responses
(IFN-	 ELISPOT) extends to escape from CD8-mediated virus-
inhibitory function. As more infectious molecular clones are gen-
erated that represent CD8 T cell escape variants in other subjects,
the frequency of escape from CD8 T cell virus inhibition during
acute infection can be better evaluated.
Transmission risk has been positively associated with viral load
in peripheral blood and mucosal secretions (5, 23, 44). Individuals
in the acute stages of HIV-1 infection, prior to viral decline and set
point, have a greater probability of passing their HIV-1 infection
to partners (42). Recently, a landmark study demonstrated that
dramatic reduction in HIV-1 viral loads by the early introduction
of antiretroviral therapy reduced the risk of transmission to sero-
negative sexual partners by 96% (10). While effective vaccine de-
signs aim to prevent HIV-1 acquisition, the likelihood of break-
through infections must be considered. Vaccine strategies that can
also elicit cellular immune responses capable of decreasing
viremia could dramatically reduce the transmission risk in the
absence of sterilizing immunity. The resultant effects at the pop-
ulation level could serve to significantly reduce the incidence of
HIV-1 globally. In addition to effects at the population level, vac-
cines that can elicit CD8 T cell populations with effective, dura-
ble, and rapid antiviral responses may reduce the cell-associated
viral load (19) and preserve CD4 T cell immunity despite infec-
tion, thus providing an overall health benefit to the individual.
Some HIV-1 vaccine strategies have been shown to elicit CD8
T cells that can inhibit virus replication (18, 53). A comparison in
future vaccine studies of the quality of the vaccine-elicited cellular
response to that of the initial inhibitory CD8 T cell response in
acute infection will be an important component in evaluating the
quality of the HIV-1 vaccine response. Proof-of-concept studies
in nonhuman primates provide evidence that effector memory
CD8 T cells at mucosal sites (24) and antigen-specific CD8 T
cell responses (38) could play a major role in protection. Thus, the
generation of CD8 T cells that can inhibit a diverse panel of
HIV-1 isolates is an important goal for vaccine design. The strat-
egy reported here of multiple CD8 T cell function assays with T/F
viruses, akin to the way neutralizing antibodies are systematically
studied (35), can provide a comprehensive platform for evaluat-
ing the quality of vaccine-elicited HIV-1-specific T cells.
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